	US 12,187,741 B2
	Glycosidase inhibitors
Anna Quattropani, Rolle (CH); Santosh S. Kulkarni, Bangalore (IN); and Awadut Gajendra Giri, Bangalore (IN)
Assigned to Asceneuron SA, Lausanne (CH)
Filed by Asceneuron SA, Lausanne (CH)
Filed on Apr. 30, 2021, as Appl. No. 17/246,143.
Application 17/246,143 is a division of application No. 16/412,689, filed on May 15, 2019, granted, now 11,046,712.
Application 16/412,689 is a continuation of application No. 15/507,375, granted, now 10,336,775, issued on Jul. 2, 2019, previously published as PCT/EP2015/069598, filed on Aug. 27, 2015.
Claims priority of application No. 2766/MUM/2014 (IN), filed on Aug. 28, 2014.
Prior Publication US 2022/0411440 A1, Dec. 29, 2022
Int. Cl. C07D 513/04 (2006.01); A61K 31/454 (2006.01); A61K 31/496 (2006.01); A61K 31/497 (2006.01); A61K 31/498 (2006.01); A61K 31/501 (2006.01); A61K 31/506 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); C07D 277/46 (2006.01); C07D 285/135 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 417/12 (2006.01); C07D 417/14 (2006.01); C07D 487/04 (2006.01)

CPC C07D 513/04 (2013.01) [A61K 31/454 (2013.01); A61K 31/496 (2013.01); A61K 31/497 (2013.01); A61K 31/498 (2013.01); A61K 31/501 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07D 277/46 (2013.01); C07D 285/135 (2013.01); C07D 401/12 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); C07D 487/04 (2013.01)]

1 Claim

1. A compound, wherein the compound is (S)-1-(1-(Benzo[d][1,3]dioxol-5-yl)ethyl)piperazine: